Immunohistochemical study of vasoactive intestinal peptide (VIP) enteric neurons in diabetic rats supplemented with L-glutamine.
The purpose of this work was to study the area of the varicosities of nerve fibers of myenteric neurons immunoreactive to vasoactive intestinal peptide (VIP-IR) and of the cell bodies of VIP-IR submucosal neurons of the jejunum of diabetic rats supplemented with 2% L-glutamine. Twenty male rats were divided into the following groups: normoglycemic (N), normoglycemic supplemented with L-glutamine (NG), diabetic (D) and diabetic supplemented with L-glutamine (DG). Whole-mounts of the muscle tunica and the submucosal layer were subjected to the immunohistochemical technique for neurotransmitter VIP identification. Morphometric analyses were carried out in 500 VIP-IR cell bodies of submucosal neurons and 2000 VIP-IR varicosities from each group. L-Glutamine supplementation to the normoglycemic animals caused an increase in the areas of the cell bodies (8.49%) and varicosities (21.3%) relative to the controls (P < 0.05). On the other hand, there was a decrease in the areas of the cell bodies (4.55%) and varicosities (28.9%) of group DG compared to those of group D (P < 0.05). It is concluded that L-glutamine supplementation was positive both to normoglycemic and diabetic animals.
Department of Morphophysiological Sciences, Laboratory of Enteric Neurons, State University of Maringa, Avenida Colombo, 5790 Bloco H-79, CEP 87020-900 Maringá, PR, Brazil. ederpaulo.uem@gmail.com
Eder Paulo Belato
EP
Alves
Angela Maria Pereira
AM
Alves
Renata Virginia Fernandes
RV
Pereira
Marcílio Hubner
MH
de Miranda Neto
Jacqueline Nelisis
JN
Zanoni
D000601:Amino Acids, Essential / Q000008:administration & dosage; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage; D001835:Body Weight; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D004032:Diet; D019587:Dietary Supplements; D017615:Enteric Nervous System / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D019084:Fluorescent Antibody Technique, Indirect; D005973:Glutamine / Q000008:administration & dosage*; D006442:Glycated Hemoglobin; D007583:Jejunum / Q000294:innervation* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009197:Myenteric Plexus / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009474:Neurons / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D020011:Protective Agents / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013368:Submucous Plexus / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism*
D000601:Amino Acids, Essential; D000975:Antioxidants; D005973:Glutamine; D006442:Glycated Hemoglobin; D020011:Protective Agents; D014660:Vasoactive Intestinal Peptide